X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.
Lead Product(s): Dantrolene
Therapeutic Area: Musculoskeletal Product Name: NPJ5008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The accelerated share repurchase program will support Eagle's multiple anticipated and ongoing drug development activities which include RYANODEX franchise, anticipated near-term launch of vasopressin, and three potential oncology launches PEMFEXY, fulvestrant and SM-88.
Lead Product(s): Dantrolene
Therapeutic Area: Musculoskeletal Product Name: Ryanodex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: JPMorgan Chase Bank
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Investment September 24, 2020
Details:
The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease. Eagle markets a formulation of dantrolene sodium but did not sponsor the study.
Lead Product(s): Dantrolene
Therapeutic Area: Neurology Product Name: Ryanodex
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
Eagle is working to increase production of RYANODEX in advance of clinical results and to potentially shorten the supply chain lead time if necessary.
Lead Product(s): Dantrolene
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020
Details:
Eagle Pharmaceuticals and the University of Pennsylvania have entered a exclusive worldwide license agreement for the development of dantrolene sodium for treatment of Alzheimer’s disease.
Lead Product(s): Dantrolene
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eagle Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2020
Details:
Under the terms of the agreement, NorthShore University HealthSystem will study Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.
Lead Product(s): Dantrolene
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eagle Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
